File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia
  • Basic View
  • Metadata View
  • XML View
TitleNot only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia
 
AuthorsWang, D1
Wong, HK1
Zhang, L4
McAlonan, GM2
Wang, XM3
Sze, SCW1
Feng, YB1
Zhang, ZJ1
 
KeywordsAntipsychotics
D2 receptors
Dopamine
Herbal medicine
Hyperprolactinemia
Peony-Glycyrrhiza Decoction (PGD)
 
Issue Date2012
 
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pnpbp
 
CitationProgress In Neuro-Psychopharmacology And Biological Psychiatry, 2012, v. 39 n. 2, p. 332-338 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.pnpbp.2012.07.005
 
AbstractClinical studies have demonstrated the effectiveness of an herbal preparation called Peony-Glycyrrhiza Decoction (PGD) in alleviating antipsychotic-induced hyperprolactinemia (hyperPRL). In the present study, we further examined the pharmacological action of PGD on prolactin (PRL) secretion using in vitro and in vivo models, with specific attention to the role of dopaminergic mediators and other sex hormones. Treatment with PGD at 1-5mg/ml significantly suppressed PRL secretion and synthesis in MMQ cells, a model of hyperPRL derived from pituitary adenoma cells. The suppressive effects were completely abolished by pretreatment with 10μM haloperidol, a dopamine D2 receptor antagonist. Consistent with a D2-action, PGD did not affect PRL in rat pituitary lactotropic tumor-derived GH3 cells that lack the D2 receptor expression but significantly increased the expression of D2 receptors and dopamine transporters (DAT) in PC12 cells. In a rat model of hyperPRL, produced by repeated injection of the dopamine blocker metoclopramide (MCP), chronic PGD (2.5-10g/kg daily) significantly reduced elevated serum PRL. The reduction in magnitude was similar to that elicited by bromocriptine (BMT), a dopamine D2 receptor agonist currently used for treatment of hyperPRL. Neither PGD nor BMT altered serum estradiol, but PGD reversed decreased serum progesterone to control level, whereas BMT did not. These results indicate that the anti-hyperPRL effects of PGD are associated not only with D2 receptor and DAT modulation, but also with a normalization of other sex hormone dysfunction. This experimental evidence supports clinical use of PGD as an effective treatment of antipsychotic-induced hyperPRL. © 2012 Elsevier Inc.
 
ISSN0278-5846
2012 Impact Factor: 3.552
2012 SCImago Journal Rankings: 1.343
 
DOIhttp://dx.doi.org/10.1016/j.pnpbp.2012.07.005
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorWang, D
 
dc.contributor.authorWong, HK
 
dc.contributor.authorZhang, L
 
dc.contributor.authorMcAlonan, GM
 
dc.contributor.authorWang, XM
 
dc.contributor.authorSze, SCW
 
dc.contributor.authorFeng, YB
 
dc.contributor.authorZhang, ZJ
 
dc.date.accessioned2012-08-16T05:57:39Z
 
dc.date.available2012-08-16T05:57:39Z
 
dc.date.issued2012
 
dc.description.abstractClinical studies have demonstrated the effectiveness of an herbal preparation called Peony-Glycyrrhiza Decoction (PGD) in alleviating antipsychotic-induced hyperprolactinemia (hyperPRL). In the present study, we further examined the pharmacological action of PGD on prolactin (PRL) secretion using in vitro and in vivo models, with specific attention to the role of dopaminergic mediators and other sex hormones. Treatment with PGD at 1-5mg/ml significantly suppressed PRL secretion and synthesis in MMQ cells, a model of hyperPRL derived from pituitary adenoma cells. The suppressive effects were completely abolished by pretreatment with 10μM haloperidol, a dopamine D2 receptor antagonist. Consistent with a D2-action, PGD did not affect PRL in rat pituitary lactotropic tumor-derived GH3 cells that lack the D2 receptor expression but significantly increased the expression of D2 receptors and dopamine transporters (DAT) in PC12 cells. In a rat model of hyperPRL, produced by repeated injection of the dopamine blocker metoclopramide (MCP), chronic PGD (2.5-10g/kg daily) significantly reduced elevated serum PRL. The reduction in magnitude was similar to that elicited by bromocriptine (BMT), a dopamine D2 receptor agonist currently used for treatment of hyperPRL. Neither PGD nor BMT altered serum estradiol, but PGD reversed decreased serum progesterone to control level, whereas BMT did not. These results indicate that the anti-hyperPRL effects of PGD are associated not only with D2 receptor and DAT modulation, but also with a normalization of other sex hormone dysfunction. This experimental evidence supports clinical use of PGD as an effective treatment of antipsychotic-induced hyperPRL. © 2012 Elsevier Inc.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationProgress In Neuro-Psychopharmacology And Biological Psychiatry, 2012, v. 39 n. 2, p. 332-338 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.pnpbp.2012.07.005
 
dc.identifier.citeulike11583355
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.pnpbp.2012.07.005
 
dc.identifier.epage338
 
dc.identifier.hkuros205007
 
dc.identifier.hkuros208633
 
dc.identifier.hkuros217179
 
dc.identifier.issn0278-5846
2012 Impact Factor: 3.552
2012 SCImago Journal Rankings: 1.343
 
dc.identifier.issue2
 
dc.identifier.pmid22796279
 
dc.identifier.scopuseid_2-s2.0-84867024470
 
dc.identifier.spage332
 
dc.identifier.urihttp://hdl.handle.net/10722/159823
 
dc.identifier.volume39
 
dc.languageeng
 
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pnpbp
 
dc.publisher.placeUnited States
 
dc.relation.ispartofProgress in Neuro-Psychopharmacology and Biological Psychiatry
 
dc.relation.referencesReferences in Scopus
 
dc.subjectAntipsychotics
 
dc.subjectD2 receptors
 
dc.subjectDopamine
 
dc.subjectHerbal medicine
 
dc.subjectHyperprolactinemia
 
dc.subjectPeony-Glycyrrhiza Decoction (PGD)
 
dc.titleNot only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Wang, D</contributor.author>
<contributor.author>Wong, HK</contributor.author>
<contributor.author>Zhang, L</contributor.author>
<contributor.author>McAlonan, GM</contributor.author>
<contributor.author>Wang, XM</contributor.author>
<contributor.author>Sze, SCW</contributor.author>
<contributor.author>Feng, YB</contributor.author>
<contributor.author>Zhang, ZJ</contributor.author>
<date.accessioned>2012-08-16T05:57:39Z</date.accessioned>
<date.available>2012-08-16T05:57:39Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Progress In Neuro-Psychopharmacology And Biological Psychiatry, 2012, v. 39 n. 2, p. 332-338</identifier.citation>
<identifier.issn>0278-5846</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/159823</identifier.uri>
<description.abstract>Clinical studies have demonstrated the effectiveness of an herbal preparation called Peony-Glycyrrhiza Decoction (PGD) in alleviating antipsychotic-induced hyperprolactinemia (hyperPRL). In the present study, we further examined the pharmacological action of PGD on prolactin (PRL) secretion using in vitro and in vivo models, with specific attention to the role of dopaminergic mediators and other sex hormones. Treatment with PGD at 1-5mg/ml significantly suppressed PRL secretion and synthesis in MMQ cells, a model of hyperPRL derived from pituitary adenoma cells. The suppressive effects were completely abolished by pretreatment with 10&#956;M haloperidol, a dopamine D2 receptor antagonist. Consistent with a D2-action, PGD did not affect PRL in rat pituitary lactotropic tumor-derived GH3 cells that lack the D2 receptor expression but significantly increased the expression of D2 receptors and dopamine transporters (DAT) in PC12 cells. In a rat model of hyperPRL, produced by repeated injection of the dopamine blocker metoclopramide (MCP), chronic PGD (2.5-10g/kg daily) significantly reduced elevated serum PRL. The reduction in magnitude was similar to that elicited by bromocriptine (BMT), a dopamine D2 receptor agonist currently used for treatment of hyperPRL. Neither PGD nor BMT altered serum estradiol, but PGD reversed decreased serum progesterone to control level, whereas BMT did not. These results indicate that the anti-hyperPRL effects of PGD are associated not only with D2 receptor and DAT modulation, but also with a normalization of other sex hormone dysfunction. This experimental evidence supports clinical use of PGD as an effective treatment of antipsychotic-induced hyperPRL. &#169; 2012 Elsevier Inc.</description.abstract>
<language>eng</language>
<publisher>Elsevier Inc. The Journal&apos;s web site is located at http://www.elsevier.com/locate/pnpbp</publisher>
<relation.ispartof>Progress in Neuro-Psychopharmacology and Biological Psychiatry</relation.ispartof>
<subject>Antipsychotics</subject>
<subject>D2 receptors</subject>
<subject>Dopamine</subject>
<subject>Herbal medicine</subject>
<subject>Hyperprolactinemia</subject>
<subject>Peony-Glycyrrhiza Decoction (PGD)</subject>
<title>Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/j.pnpbp.2012.07.005</identifier.doi>
<identifier.pmid>22796279</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84867024470</identifier.scopus>
<identifier.hkuros>205007</identifier.hkuros>
<identifier.hkuros>208633</identifier.hkuros>
<identifier.hkuros>217179</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84867024470&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>39</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>332</identifier.spage>
<identifier.epage>338</identifier.epage>
<publisher.place>United States</publisher.place>
<identifier.citeulike>11583355</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong Li Ka Shing Faculty of Medicine
  2. King's College London
  3. National Institute of Nursing Research
  4. National Institute on Alcohol Abuse and Alcoholism